Literature DB >> 32059632

Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.

Michael C Honigberg1, Orly Vardeny2, Muthiah Vaduganathan3.   

Abstract

Entities:  

Keywords:  diabetes mellitus; drug therapy, combination; heart failure

Mesh：

Substances：

Year:  2020        PMID： 32059632      PMCID： PMC7543063          DOI： 10.1161/CIRCHEARTFAILURE.119.006623

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  11 in total

Review 1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2017-04-28       Impact factor: 29.690

2.  Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.

Authors:  Muthiah Vaduganathan; Vasanth Sathiyakumar; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt
Journal:  J Am Coll Cardiol       Date:  2018-12-25       Impact factor: 24.094

3.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

Review 4.  Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.

Authors:  Aditi A Bhagat; Stephen J Greene; Muthiah Vaduganathan; Gregg C Fonarow; Javed Butler
Journal:  JACC Heart Fail       Date:  2018-11-07       Impact factor: 12.035

5.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

Review 6.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

7.  2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Authors:  Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; William T Cefalu; James L Januzzi; Rita Rastogi Kalyani; Mikhail Kosiborod; Melissa L Magwire; Pamela B Morris; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2018-11-26       Impact factor: 24.094

8.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

Authors:  Stephen J Greene; Javed Butler; Nancy M Albert; Adam D DeVore; Puza P Sharma; Carol I Duffy; C Larry Hill; Kevin McCague; Xiaojuan Mi; J Herbert Patterson; John A Spertus; Laine Thomas; Fredonia B Williams; Adrian F Hernandez; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2018-07-24       Impact factor: 24.094

9.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

Review 10.  Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.

Authors:  Orly Vardeny; Muthiah Vaduganathan
Journal:  JACC Heart Fail       Date:  2019-02       Impact factor: 12.035
View more
  5 in total

1.  Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.

Authors:  Mohammed Somaili; Omar Oraibi; Mostafa Mohrag; Abdelrahman Hommadi; Esam Moafa; Abdulrahman Kulaybi; Sahar Shobayli; Razan Moafa; Ghadah Mhgfory; Afaf Jaafari; Ayman Shami; Khalid Majrashi
Journal:  Cureus       Date:  2022-04-19

Review 2.  Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.

Authors:  Ammar G Chaudhary; Fadi M Alreefi; Mohammad A Aziz
Journal:  CJC Open       Date:  2021-02-01

3.  Weighted gene co-expression network analysis to define pivotal modules and genes in diabetic heart failure.

Authors:  Weiwei Liang; FangFang Sun
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

Review 4.  What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

Authors:  Muhammad Shahzeb Khan; Muthiah Vaduganathan
Journal:  Curr Diab Rep       Date:  2020-10-11       Impact factor: 4.810

Review 5.  Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.

Authors:  Magdy Abdelhamid; Hossam Kandil; Mahmoud Hassanin; Sameh Shaheen; Mohamed Sobhy; Adel ElEtreby; Hosam Hasan-Ali; Hala Mahfouz; Gamila Nasr; Islam Shawky; Sameh Emil; Mohamed ElSetiha; Mohamed Hasssan; Yasser Sadek; Mohamed Abdelghany Karim; Ayman Asham; Mohamed Ghaleb; Ahmad Samir; Khaled Shokry
Journal:  ESC Heart Fail       Date:  2022-02-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.